scholarly journals Graves’ Disease Following Subacute Thyroiditis

2021 ◽  
Vol 6 (2) ◽  
pp. 67-70
Author(s):  
Young Sik Choi
Keyword(s):  
Thyroid Disease ◽  
Subacute Thyroiditis ◽  
Graves Disease ◽  
Thyroid Ultrasonography ◽  
Anterior Neck ◽  
Autoimmune Thyroid ◽  
Vascular Flow ◽  
Thyroid Function Testing ◽  
Swallowing Difficulty ◽  
Function Testing

Subacute thyroiditis is an inflammatory thyroid disease caused by viral infection. Graves’ disease is an autoimmune thyroid disease caused by thyrotropin (TSH) receptor antibody (TRAb). Graves’ disease following subacute thyroiditis is rare, and only a few cases have been reported. A 58-year-old woman presented with anterior neck pain and swallowing difficulty. Laboratory tests showed elevated FT4, low TSH, normal TRAb, and elevated erythrocyte sedimentation rate. Thyroid ultrasonography (US) revealed focal, ill-defined hypoechoic areas in both thyroid lobes. The patient was treated with corticosteroid, and symptoms subsided after 1 month. Three months later, she complained of tremor and palpitation. Thyroid function testing showed hyperthyroidism with the positive conversion of TRAb, indicating Graves’ disease. Doppler US showed increased vascular flow in both thyroid lobes. She started treatment for hyperthyroidism with methimazole.

scholarly journals A Case of Thyrotoxicosis due to Simultaneous Occurrence of Subacute Thyroiditis and Graves’ Disease

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
Kazunori Kageyama ◽  
Noriko Kinoshita ◽  
Makoto Daimon
Keyword(s):  
Thyroid Hormones ◽  
Thyroid Disease ◽  
Rare Case ◽  
Autoimmune Thyroid Disease ◽  
Subacute Thyroiditis ◽  
Simultaneous Occurrence ◽  
Graves Disease ◽  
Inflammatory Disorder ◽  
Autoimmune Thyroid ◽  
Prompt Diagnosis

Subacute thyroiditis is an inflammatory disorder of the thyroid. Graves’ disease is an autoimmune thyroid disease in which thyroid hormones are overproduced. Here we present a rare case of thyrotoxicosis due to the simultaneous occurrence of both diseases. Prompt diagnosis and therapy are required to prevent complications in patients with thyrotoxicosis.

scholarly journals COVID19 Associated Painful Subacute Thyroiditis

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A926-A926
Author(s):  
Pooja Bhargava ◽  
Devin Warren Steenkamp
Keyword(s):  
Thyroid Disease ◽  
Left Lobe ◽  
Subacute Thyroiditis ◽  
Prior History ◽  
Free T4 ◽  
Autoimmune Thyroid ◽  
Vascular Flow ◽  
History Of ◽  
Uptake Test ◽  
The Right

Abstract Objective: Physicians should be aware that thyroiditis is a potential sequela of COVID-19 infection. Discussion: A 49-year-old female without any prior history of thyroid dysfunction presented with clinical and biochemical hyperthyroidism after a diagnosis of COVID-19 illness four months ago. At the time of thyroiditis diagnosis: free T4 was 1.52 ng/dL (normal, 0.76-1.46 ng/dL), TSH <0.005 uIU/mL (normal, 0.358-3.74 uIU/mL), Thyroglobulin antibodies 2 IU/mL (normal, <=1 IU/mL), TPO antibody 1 IU/mL (normal, <9 IU/mL), ESR 5 mm/hr (normal, 0-20 mm/hr). Thyroid US showed no nodules or evidence of autoimmune thyroid disease or abnormal vascular flow. A radioactive iodine uptake test was performed through the primary care office. The test demonstrated symmetric, uniform radiotracer uptake in the right and left lobe. 24-hour uptake was low at 0.1% (normal 15-25%) indicating thyroiditis. Patient features consistent with the diagnosis of subacute thyroiditis include suppressed TSH, diffuse tenderness on thyroid palpation, absent TPO/TG antibodies, and suppressed I-123 RAI uptake (<1%) on 24-hour scan. Conclusion: There is limited data surrounding thyroid disease and COVID-19. It has been suggested that a possible sequela of COVID-19 is thyroiditis. Physicians caring for recovering COVID-19 patients should be aware of possible painful subacute thyroiditis and to check thyroid studies in persons with symptoms of thyrotoxicosis post-COVID-19.

scholarly journals Case Report: De Quervain’s Thyroiditis as a Long-Term Sequelae Complication to SARS-CoV-2 Infection

2021 ◽  
pp. 64-70
Author(s):  
Mark Kong ◽  
Sarah La Porte
Keyword(s):  
Case Report ◽  
Thyroid Function ◽  
Elevated Serum ◽  
Subacute Thyroiditis ◽  
Thyroid Function Tests ◽  
Thyroid Function Testing ◽  
Neck Lump ◽  
Function Testing

A 44-year-old man presented with an enlarged painful lower anterior neck lump with elevated serum concentrations of free thyroxine (T4) and tri-iodothyronine (T3), alongside the presence of antithyroid peroxidase antibodies. Prior to presentation, the patient was demonstrating recovery from a SARS-CoV-2 infection that required sedation, intubation, and invasive ventilation in the intensive care unit (ICU) for 11 days. Ultrasound examination of the thyroid demonstrated features of De Quervain’s (subacute) thyroiditis. This corresponded to the clinical picture, and continuous thyroid function tests were arranged. Emerging evidence throughout the SARS-CoV-2 pandemic describes the long-term sequelae of the infection, including developing atypical effects on the thyroid gland. This case report emphasises the association of painful subacute thyroiditis with post-viral infection and its manifestation during recovery from severe SARS-CoV-2, suggesting that follow-up thyroid function testing should be considered in patients discharged from the ICU who develop neck discomfort.

Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response

2020 ◽  
Vol 105 (9) ◽  
pp. e3392-e3399 ◽  
Author(s):  
Alina Sovetkina ◽  
Rans Nadir ◽  
Antonio Scalfari ◽  
Francesca Tona ◽  
Kevin Murphy ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Graves Disease ◽  
Autoimmune Thyroid ◽  
Tertiary Referral Center ◽  
T2 Lesions ◽  
Relapsing Remitting ◽  
Edss Score ◽  
Multiple Sclerosis Patients

Abstract Context Alemtuzumab is an anti-CD52 monoclonal antibody used in the treatment of relapsing-remitting multiple sclerosis (MS). Between 20% and 40% of alemtuzumab-treated MS patients develop autoimmune thyroid disease (AITD) as a side effect. Objective The objective of this work is to determine whether MS disease progression following alemtuzumab treatment differs in patients who develop AITD compared to those who do not. Design, Setting, and Patients A retrospective analysis of 126 patients with relapsing-remitting MS receiving alemtuzumab from 2012 to 2017 was conducted at a tertiary referral center. Main Outcome Measures Thyroid status, new relapses, Expanded Disability Status Scale (EDSS) score change, and disability progression following alemtuzumab were evaluated. Results Twenty-six percent (33 out of 126, 25 female, 8 male) of alemtuzumab-treated patients developed AITD, 55% of which was Graves disease. EDSS score following alemtuzumab was reduced in patients who developed AITD compared to those who did not (median [interquartile range]; AITD: –0.25 [–1 to 0.5] vs non-AITD: 0 [1-0]. P = .007]. Multivariable regression analysis confirmed that the development of AITD was independently associated with EDSS score improvement (P = .011). Moreover, AITD patients had higher relapse-free survival following alemtuzumab (P = .023). There was no difference in the number of new focal T2 lesions and contrast-enhancing magnetic resonance imaging lesions developed following alemtuzumab between the 2 groups. Conclusion Graves disease was the most common form of AITD developed by MS patients following alemtuzumab. This study suggests that MS patients who develop AITD may have an improved response to alemtuzumab, as measured by reduced disability and lower relapse rate.

Surgical Excision of Pseudotumorous Pretibial Myxedema

1996 ◽  
Vol 17 (2) ◽  
pp. 107-110 ◽  
Author(s):  
A. Pingsmann ◽  
H. M. Ockenfels ◽  
Th. Patsalis
Keyword(s):  
Local Excision ◽  
Thyroid Disease ◽  
Clinical Course ◽  
Surgical Excision ◽  
Clinical Feature ◽  
Graves Disease ◽  
Disease Treatment ◽  
Autoimmune Thyroid ◽  
Clinical Control ◽  
Pretibial Myxedema

Pretibial myxedema is a well-known clinical feature of autoimmune thyroid malfunction and is classically associated with Graves’ disease. Its clinical course is frequently not related to the clinical control of the underlying thyroid disease. Treatment is primarily medical, consisting of oral and topical corticosteroids. We present a case of successful local excision of a pseudotumorous manifestation at the dorsum of the foot recalcitrant to multimodal medical and dermatological therapy.

Serum myoglobin in thyroid disease

1980 ◽  
Vol 94 (2) ◽  
pp. 184-187 ◽  
Author(s):  
F. A. Karlsson ◽  
P. A. Dahlberg ◽  
P. Venge ◽  
L. E. Roxin
Keyword(s):  
Thyroid Disease ◽  
Healthy Subjects ◽  
Reference Range ◽  
Subacute Thyroiditis ◽  
Graves Disease ◽  
Thyroid Disorders ◽  
Muscular Weakness ◽  
De Quervain ◽  
Serum Myoglobin

Abstract. Serum myoglobin levels were measured longitudinally in patients undergoing therapy because of various thyroid disorders. Elevated myoglobin values - 72.6 (58.7–89.7) μg/l (mean ± sem) were found in a group of hypothyroid subjects. The degree of myoglobin increase seemed related to the severity of hypothyroidism. When rendered euthyroid the myoglobin levels of these patients were normalized − 41.0 (37.3–45.1) μg/l. In patients with hyperthyroidism, due to Graves' disease or subacute thyroiditis (de Quervain), only minor changes of myoglobin values within the reference range of healthy subjects, were measured. This suggests that mechanisms not affecting myoglobin release are responsible for the muscular weakness of thyrotoxic patients.

scholarly journals Autoimmune Thyroid Disease and Psoriasis Vulgaris after COVID-19 in a Male Teenager

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Nadia K. Qureshi ◽  
Sanjay K. Bansal
Keyword(s):  
Family History ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Psoriasis Vulgaris ◽  
Thyroid Diseases ◽  
Graves Disease ◽  
Healthy Male ◽  
Autoimmune Thyroid

COVID-19 is implicated in triggering autoimmune, dermatologic, and thyroid diseases. We present a first known case of development of Graves’ disease and psoriasis vulgaris in a previously healthy male teenager without any family history, diagnosed after COVID-19 infection. Evaluation of “long COVID syndrome” should include thorough history and thyroid evaluation.

scholarly journals Co-existent ocular myasthenia gravis and Graves’ disease in a 5 year old

2021 ◽  
Vol 2 (4) ◽  
Author(s):  
Olivia Watson ◽  
Michelle Jack ◽  
Helen Young
Keyword(s):  
Myasthenia Gravis ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Clinical Presentation ◽  
Graves Disease ◽  
Autoimmune Thyroid ◽  
Ocular Myasthenia ◽  
Ocular Myasthenia Gravis ◽  
The Relationship ◽  
Symptom Recurrence

Myasthenia gravis and Graves’ disease are known to co-exist in adults, yet there have only been a small number of paediatric cases reported. We report a 5 year old female who was diagnosed with ocular myasthenia gravis after presenting with unilateral ptosis and subsequently found also to have Graves’ disease. She was treated successfully with pyridostigmine, corticosteroids and carbimazole without symptom recurrence or progression to generalised myasthenia gravis. The aetiology of the coexistence is not fully understood, nor is the relationship between the two disorders’ presentation and treatment. We discuss the variation in clinical presentation of myasthenia gravis between populations and when associated with autoimmune thyroid disease, potential HLA-related genetic susceptibility and the varying approaches to treatment of the co-existent disorders.

Sign in / Sign up

Export Citation Format

Share Document